Data from Pharmawand - Curated by EPG Health - Date added 23 October 2013
NeuroAiD, from Moleac, reduces early cardiovascular events and deaths by nearly 50% on top of antiplatelet agents within three months in patients after Stroke onset, without an increase in bleeding rate and non-vascular deaths according to research published in the journal Stroke. The CHIMES study is an international double-blind placebo-controlled clinical trial in 1099 patients having suffered an ischemic stroke of intermediate severity within 72 hours, treated by NeuroAiD or placebo and monitored for 3 months.
NeuroAiD may have an effect on preventing the occurrence of early vascular events after stroke onset: the vascular outcome occurred in 16 patients (2.9%) of the NeuroAiD group, as opposed to 31 patients (5.6%) in the placebo group. This represents half the rate of early cardiovascular events and deaths, which corresponds to about 27 fewer patients suffering a recurrent vascular event or death per 1000 patients treated over 3 months. Patients on NeuroAiD having fewer adverse events than those in the placebo group. See: "Effects of MLC601 on Early Vascular Events in Patients After Stroke: The CHIMES Study." Chen CLH et al. Stroke 2013; 44 October 17, 2013. doi: 10.1161/STROKEAHA.113.003226